Agenda
Click here for a downloadable version of the agenda. All times listed are Eastern.
| Welcome and Opening Remarks | |
| 9:00 AM | NINDS Welcome Walter J. Koroshetz, MD Director, National Institute of Neurological Disorders and Stroke |
| 9:10 AM | Engaging the Lived Experience Perspective on PD Therapeutics Rebekah Corlew, PhD Lived Experience Engagement Strategist, National Institute of Neurological Disorders and Stroke |
| Keynote Address: Landscape of PD Therapeutics Development | |
| 9:20 AM | Workshop Co-Chairs Welcome and Goals for the 2 Days Alice Chen-Plotkin, MD Parker Family Professor of Neurology, University of Pennsylvania Bill Martin, PhD Global Neuroscience Therapeutic Area Head, Johnson & Johnson Innovative Medicine |
| 10:00 AM | Break (5 minutes) |
| Session 1: PD Heterogeneity Moderator: Karl Kieburtz, MD, MPH, Professor, University of Rochester | |
| 10:05 AM | Motor Heterogeneity in Parkinson’s Disease: Challenges to Therapeutic Developments Anthony Lang, MD, FRCPC Director, Edmond J Safra Program in Parkinson’s Disease, University of Toronto |
| 10:20 AM | Heterogeneity of Non-Motor Symptoms across Lewy Body Diseases Kathleen Poston, MD, MS, Edward F. and Irene Thiele Pimley Professor in Neurology and Neurological Sciences, Director, Stanford Movement Disorders Center, Stanford University |
| 10:35 AM | Q & A Discussion (30 minutes) |
| 11:05 AM | Break (10 minutes) |
| Session 2: Target Validation Moderator: Alice Chen-Plotkin, MD, Parker Family Professor of Neurology, University of Pennsylvania | |
| 11:15 AM | Evolving Arcs toward Disease-Modifying Therapy for Parkinson’s Michael Schwarzschild, MD, PhD Professor of Neurology, Massachusetts General Hospital, Harvard Medical School |
| 11:30 AM | Targeting LRRK2: Why, Who, Where and When Mark R. Cookson, PhD National Institute on Aging |
| 11:45 AM | An Industry Perspective on Target Validation For Neurologic Diseases David Stone, PhD VP, Head of Genetics and Target Identification, Cerevel Therapeutics, LLC |
| 12:00 PM | Q & A Discussion (30 minutes) |
| 12:30 PM | Lunch (60 minutes) |
| Session 3: Appropriate Tools to Enable Therapeutics Development Moderator: Shalini Padmanabhan, PhD, Vice President, Discovery & Translational Research, Michael J. Fox Foundation | |
| 1:30 PM | Teeing Up a Discussion about Appropriate Tools to Enable Therapeutics Development Patrik Brundin, MD, PhD Distinguished Scientist/Therapeutic Area Leader for Movement Disorders, Roche |
| 1:45 PM | Preclinical Tools to Advance Parkinson Disease Therapeutics: What They Can and Cannot Do Laura Volpicelli-Daley, PhD Associate Professor, University of Alabama at Birmingham |
| 2:00 PM | Q & A Discussion (30 minutes) |
| 2:30 PM | Break (10 minutes) |
| Session 4: Biomarker Use Moderator: Danielle Graham, PhD, Head of Fluid Biomarkers and Bioanalysis, Biogen | |
| 2:40 PM | AI-Enabled Biomarkers: A Window into Parkinson’s Progression, Detection, and Treatment Response Dina Katabi, PhD Thuan and Nicole Pham Professor, Massachusetts Institute of Technology |
| 2:55 PM | Identification of Proteomic Targets and Biomarkers: The Mapping Proteomics to Parkinson’s Disease Project (MAP2PD) Laura Winchester, DPhil Research Fellow, University of Oxford |
| 3:10 PM | Understanding Biomarker Parameters to Enable Clinical Trials in Parkinson’s Disease Danielle Graham, PhD Head of Fluid Biomarkers and Bioanalysis, Biogen |
| 3:25 PM | Q & A Discussion (30 minutes) |
| 3:55 PM | Break (15 minutes) |
| Breakout Session Day 1 | |
| 4:10 PM | Parallel Breakout Session What is missing that is holding back therapeutics development? |
| 4:55 PM | Break (5 minutes) |
| End of Day 1 | |
| 5:00 PM | Day 1 Wrap-up |
| 5:10 PM | Adjourn for the day |
Click here for a downloadable version of the agenda. All times listed are Eastern.
| Welcome and Day 2 Opening Remarks | |
| 8:45 AM | Workshop Co-Chairs Welcome Alice Chen-Plotkin, MD Parker Family Professor of Neurology, University of Pennsylvania Bill Martin, PhD Global Neuroscience Therapeutic Area Head, Johnson & Johnson Innovative Medicine |
| Breakout Session Reports from Day 1 | |
| 8:55 AM | Reports from Breakout Sessions and Q & A Breakout Reports by the breakout session leaders followed by general discussion. |
| 10:00 AM | Break (10 minutes) |
| Session 5: Lessons from PD Adjacent Communities Moderator: Amir Tamiz, PhD, Director, Division of Translational Research, National Institute of Neurological Disorders and Stroke | |
| 10:10 AM | Disease-Modifying Therapies: Lessons from Alzheimer’s Disease Drug Development Jeffrey Cummings, MD, ScD Director, Chambers-Grundy Center for Transformative Neuroscience, University of Nevada Las Vegas, School of Integrated Health Sciences, Department of Brain Health |
| 10:25 AM | RNA-Target Therapies for Neurodegenerative Disease Timothy M. Miller, MD, PhD David Clayson Professor of Neurology, Washington University School of Medicine |
| 10:40 AM | Q & A Discussion (30 minutes) |
| 11:10 AM | Break (10 minutes) |
| Session 6: Best Practices for Advancing Development Moderator: Bill Martin, PhD, Global Neuroscience Therapeutic Area Head, The Janssen Pharmaceutical Companies of Johnson & Johnson | |
| 11:20 AM | Addressing the Academia-Industry Gap to Advance Discoveries to the Clinic Opher Kornfeld, PhD Director, Translational Research and Development, SPARK NS |
| 11:35 AM | LRRK2 Inhibitors: From Basic Biology to the Clinic Anastasia Henry, PhD Director and Principal Scientist, Denali Therapeutics |
| 11:50 AM | Opportunities and Challenges in Parkinson’s Disease Clinical Development using the Example of the SCD Inhibitor YTX-7739 Fiona Elwood, PhD VP, Disease Area Leader Neurodegeneration, Neuroscience, Johnson & Johnson Innovative Medicine |
| 12:05 PM | Q & A Discussion (30 minutes) |
| End of Day 2 | |
| 12:35 PM | Day 2 Wrap-up |
| 12:45 PM | Adjourn / Lunch (75 minutes) |
| Optional Breakout Session Day 2 | |
| 2:00 PM | Parallel breakout sessions
|
| 3:00 PM | Adjourn |